Luke Liu, MD
Interventional Pain Medicine · Anchorage, AKNPI 1942413349
Payments from drug & device makers
Across 182 payments — averaging $228.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$23K
- Medtronic$15K
- Globus Medical$1K
- Stryker$929
- Abbott$341
- Stimwave Technologies Incorporated$299
- plus $1K from 16 others
Across 2 payments — averaging $1315.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$3K
What the payments were for
- Travel & lodging$1,75038%
- Food & beverage$2,86862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 26 | $23,038 |
| Medtronic(2 entities) | 89 | $14,946 |
| Globus Medical | 2 | $1,052 |
| Stryker | 4 | $929 |
| Abbott | 18 | $341 |
| Stimwave Technologies Incorporated | 4 | $299 |
| Vertos Medical, Inc. | 2 | $195 |
| AbbVie | 9 | $188 |
| Collegium Pharmaceutical, Inc. | 8 | $142 |
| Ipsen Biopharmaceuticals, Inc | 2 | $91 |
| Tersera Therapeutics LLC | 2 | $69 |
| Avanos Medical | 1 | $64 |
| Averitas Pharma Inc. | 2 | $51 |
| Assertio Therapeutics, Inc. | 3 | $50 |
| Boston Scientific | 1 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Pfizer | 2 | $27 |
| Merz Pharmaceuticals, LLC | 1 | $24 |
| Pacira Therapeutics, Inc. | 1 | $20 |
| GRT US Holding, Inc. | 1 | $16 |
| Si-bone, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few interventional pain medicine providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Topiramate | 11 | $1,093 |
| Gabapentin | 50 | $853 |
| Pregabalin | 11 | $621 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $221 |
| Tizanidine Hcl | 18 | $152 |
| Cyclobenzaprine Hcl | 15 | $107 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Anchorage
- Steven JohnsonAnchorage$3K
- Lawrence KroppAnchorage$218
- Christopher GayFairbanks$16K
- John GrissomWasilla$3K
- Eric SeversonWasilla$712
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.